Background
In the proteomics era, significant effort has been devoted to developing techniques that accurately and efficiently determine differences in protein amounts under normal physiological conditions and disease states [
1]. However, quantifying protein turnover rates at both a cellular and systemic level is also necessary for a complete understanding of the mechanisms dictating changes in protein levels [
2]. Several neurodegenerative diseases are characterized by the accumulation of protein aggregates in the brain, including Alzheimer’s disease (AD) [
3], Parkinson’s disease [
4], Huntington’s disease [
5], and frontotemporal dementia[
6]. Although the underlying cause of protein aggregation in these diseases remains unclear, it is likely due to abnormal proteostasis caused by alterations in protein production or clearance [
7,
8]. Therefore, the development of techniques that can assess protein dynamics in the brain are fundamental for advancing our understanding of these disease processes and aiding the conception of innovative therapeutics.
Stable isotope tracers have been in use for many years to facilitate the analysis of protein turnover in cells and whole organisms [
9]. Mass spectrometry (MS) has proven an effective tool for the analysis of stable isotope incorporation into individual proteins [
10]. Liquid chromatography-mass spectrometry (LC-MS) analysis allows for the comparison of the relative abundance of labeled to unlabeled peptides due to their mass separation. Coupling stable isotope amino acid labeling with LC-MS has been applied to quantify protein synthesis and degradation in yeast [
11], mammalian cell lines [
12,
13], and small animals [
14,
15]. However, protein turnover studies in animals have been limited due to issues with MS detection sensitivity and accurate label quantification, along with difficulties in achieving cost-effective and practical methods for tracer administration. Recently, Bateman
et al. have developed a method to measure the dynamics of low abundance proteins in the cerebral spinal fluid (CSF) of humans [
16]. In this technique,
13 C
6-leucine is injected intravenously into research participants and samples of the lumbar CSF are serially collected over a predetermined time period. The synthesis and clearance rates of proteins are then measured by quantifying the appearance and disappearance of the
13 C
6-leucine in proteins over time via LC-MS [
16,
17]. The value of this technique has specifically been highlighted for the amyloid β (Aβ) peptide, which accumulates in the brains of AD patients and has been implicated in the disease pathogenesis [
3]. Application of stable isotope labeling to studies of Aβ dynamics have demonstrated impaired Aβ clearance in individuals with AD and the ability of a gamma secretase inhibitor to decrease Aβ synthesis in the CNS [
8,
16,
18].
Apolipoprotein E (apoE) plays a central role in the transport of cholesterol by functioning as a ligand for the receptor-mediated endocytosis of lipoprotein particles into cells [
19]. In humans, three common apoE isoforms exist (apoE2, apoE3, and apoE4) that differ by amino acids at positions 112 and 158. ApoE4 is currently the strongest known genetic risk factor for late-onset AD, and as a result significant effort has been devoted to understanding apoE’s physiological function in the brain along with its role in AD pathogenesis [
20]. A major hypothesis for how apoE4 affects the onset of AD contends that apoE promotes the aggregation of Aβ into amyloid plaques in the brain, either through impairing Aβ clearance [
21,
22], directly regulating the propensity of Aβ to form amyloid fibrils [
23,
24], or both mechanisms. Independent of apoE isoform, the amount of apoE in the brain appears to be critical for determining the extent of amyloid deposition [
25,
26]. Therefore, finding proteins and molecular pathways that regulate apoE levels in the brain has been the focus of significant attention in the AD research community.
Increasing the endocytosis of apoE via the low-density lipoprotein receptor (LDLR) has been shown to decrease apoE levels in the mouse brain, likely through increased apoE clearance [
27]. Brain levels of the cholesterol transporter ATP binding cassette A1 (ABCA1) also alter the amount of apoE and the extent of apoE lipidation in mice. Both the overexpression and deletion of ABCA1 in the mouse brain resulted in a decrease in apoE protein level [
28‐
30]. In transgenic mice that overexpress the human amyloid precursor protein (APP), increasing ABCA1 levels caused a significant decrease in amyloid deposition in the brain [
30]. Therefore, it has been hypothesized that ABCA1 regulates amyloid levels in the brain by altering Aβ clearance, and this could occur through the effect of ABCA1 on either apoE lipidation or total apoE levels. However, no study has yet addressed this hypothesis formally by studying apoE and Aβ metabolism in the brain of mice with altered ABCA1 levels.
Herein, we describe a novel method to study protein clearance in the mouse brain. We show that following a bolus injection of 13 C6-leucine into mice, LC-MS analysis of brain tissue can be used to measure the fractional clearance rate (FCR) of individual proteins. We validate our technique by analyzing changes in the clearance of apolipoprotein E (apoE) in mice that have been genetically engineered to overexpress LDLR. Finally, we use 13 C6-leucine labeling coupled to LC-MS analysis to measure the clearance of apoE and Aβ in APP transgenic mice that either overexpress or lack ABCA1. Both overexpression and deletion of ABCA1 resulted in an increased fractional clearance rate of apoE. However, ABCA1 levels did not alter the clearance rate of Aβ in the mouse brain, suggesting ABCA1 acts via another pathway, such as directly influencing Aβ aggregation, to regulate amyloid deposition. These results highlight the power of our stable isotope labeling technique in elucidating mechanisms of protein clearance from the brain, and suggest that future studies could use this technique to study the clearance pathways of other proteins implicated in neurodegenerative disease.
Conclusions
In this study, we describe a stable isotope pulse labeling kinetics (SILK) technique that can be used to measure the clearance of proteins from the mouse brain. The non-radioactive labeling method is safe, straightforward, and does not require administration of the stable isotope via the diet. Label administration to the mice is consistent and easily controlled by altering the amount injected. Since the stable isotope quickly appears in both plasma and brain within minutes of the injection, this technique is particularly suitable for measuring the kinetics of proteins that turn over rapidly. The SILK technique is not particularly expensive and can be applied in any laboratory setting that has access to MS instrumentation. The primary costs associated with this technique are the purchase of the stable isotope and the generation and maintenance of the mice prior to injection. In terms of time, the labeling of the mice and collection of tissue is the most laborious aspect of this technique. Once the brain tissue is collected for the whole cohort of mice, preparation and processing of the samples for MS analysis is extremely efficient because all of the samples can be processed in parallel. It takes about one week to complete the labeling of mice and preparation of samples for MS analysis.
We demonstrate that this labeling technique is particularly useful for comparing the kinetics of a protein in cohorts of mice with different genetic manipulations. To show the applicability of this technique to test a hypothesis pertinent to neurodegenerative disease, the effect of ABCA1 levels on the clearance of Aβ from the mouse brain were measured
in vivo for the first time. Increasing ABCA1 or deleting ABCA1 from the brain had no effect on Aβ clearance. Consequently, ABCA1 likely regulates Aβ deposition in the brain through a mechanism other than altering Aβ metabolism, such as through modulating the propensity of Aβ to aggregate. Previous studies have measured Aβ clearance from the brain either using
35 S]methionine labeling [
48], or by measuring the disappearance of Aβ following the pharmacological inhibition of Aβ production [
49‐
51]. The half-life of Aβ clearance in these studies ranged from 30 min to 2 h. Consistent with these studies, we observed a half-life for Aβ of approximately 2.8-2.9 h (Table
3). In comparison to other studies, our technique has unique advantages in that it does not require a radioactive tracer and kinetics are determined in the steady-state, which does not occur with the inhibition of Aβ production.
We propose that this method of stable isotope labeling, and its applicability to studying the clearance of proteins in genetically modified mouse models, will be useful in studying the kinetics of proteins implicated in other neurodegenerative diseases, such as synuclein, tau, and huntingtin. We also hope that this technique will aid the development and characterization of novel therapeutics that target protein metabolism in neurodegeneration.
Methods
Materials
13 C6-leucine was obtained from Cambridge Isotope Laboratories (Andover, MA, USA). HJ5.2 (Aβ) and HJ6.3 (ApoE) antibodies were made in-house. Protein G Sepharose 4 Fast Flow beads were obtained from GE Healthcare (Piscataway, NJ, USA). Formic acid (Optima LC-MS) was obtained from Fisher Scientific and triethylammonium bicarbonate was obtained from Sigma-Aldrich (St. Louis, MO, USA). Trypsin Gold (mass spec grade) was purchased from Promega (Madison, WI, USA).
Animal labeling and tissue collection
The production and characterization of the LDLR transgenic and ABCA1 transgenic mice have been previously described [
27,
30]. ABCA1
+/− mice on a DBA background were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). PDAPP mice on a C57/BL/6J background were a generous gift from Eli Lilly (Indianapolis, IN, USA). LDLR Tg
+/− mice were bred to Wt mice to generate mice that were LDLR Tg
+/− and LDLR Tg
−/−. ABCA1 Tg mice were backcrossed to C57/BL/6J mice for 8 generations, and then crossed to DBA mice. PDAPP mice were also crossed to DBA mice and ABCA1
+/− mice were crossed to C57/BL/6J mice to create strains that were on a 50% C57/BL/6J/50%DBA background. The ABCA1 Tg
+/− and PDAPP
+/− mice were then bred to each other to generate ABCA1 Tg
+/−/PDAPP
+/− and ABCA1 Tg
−/−/PDAPP
+/− mice that were used for the experiments. ABCA1
+/− were crossed to PDAPP
+/− mice to generate mice that were PDAPP
+/−/ABCA1
+/−. These mice were then bred to ABCA1
+/− mice to generate mice that were PDAPP
+/−/ABCA1
+/+, PDAPP
+/−/ABCA1
+/−, and PDAPP
+/−/ABCA1
−/−. The PDAPP
+/−/ABCA1
+/+ and PDAPP
+/−/ABCA1
−/− mice were used for all experiments. Mice were maintained under constant light/dark conditions and had free access to food and water. All experimental protocols were approved by the Animal Studies Committee at Washington University in St. Louis.
Prior to injection, the 13 C6-leucine was dissolved in medical-grade normal saline to a concentration of 7.5 mg/mL. The mice were weighed and then intraperitoneally injected with the 13 C6-leucine (200 mg/kg of body weight). After predetermined time points, the animals were anesthetized and the blood was collected by cardiac puncture. The mice were then perfused with PBS-heparin and regional brain dissection was performed. All brain samples were subsequently frozen on dry ice.
Primary astrocyte cell culture and in vitro labeling
Primary astrocytes were cultured from postnatal day (P1) C57/BL/6J mouse pups as described previously [
27]. Cells were cultured in serum-containing growth media (DME/F12, 15% fetal bovine serum, 10 ng/mL epidermal growth factor, 100 units/mL penicillin/streptomycin, and 1 mM sodium pyruvate) until they reached 70% confluency. The cell media was then changed to serum free media that did not contain any leucine (DME/F12 without leucine prepared by the Washington University Tissue Culture Support Center, N2 growth supplement, 100 units/mL penicillin/streptomycin, and 1 mM sodium pyruvate) and cultured for 12 h.
13 C
6-leucine was then diluted into unlabeled leucine to make labeled/unlabeled percentages that were either 0, 1.25, 2.5, 5, 10, or 20%. These different percent-labeled leucine solutions were then added to separate flasks of primary astrocytes, and the cells were cultured for an additional 48 h. The media was then collected from the cells, spun down at 1500 rpm to clear cellular debris, and stored at −80°C.
ApoE and Aβ immunoprecipitation
Antibody beads were prepared by covalently binding either HJ6.3 (apoE) or HJ5.2 (Aβ) to Protein G Sepharose 4 Fast Flow beads. The beads initially were washed 3 times with ice-cold PBS and then resuspended in ice-cold PBS to make a 50% slurry of beads. 300 μL of the washed 50% beads were then mixed with antibody (0.4 μg/μL of 50% bead mixture), 10 μL of 1% Triton X-100 and ice-cold PBS to make a final volume of 1000 μL. This mixture was then tumble incubated overnight at 4°C. The beads were then washed 3 times with 1% Triton X-100 lysis buffer (Triton X-100, 150 mM NaCl, 50 mM Tris–HCl) and 2 times with 0.2 M triethanolamine (pH = 8.2). Freshly prepared dimethyl pimelimidate in 0.2 M triethanolamine (pH = 8.2) was then added to the beads, followed by a 30 min incubation with tumbling at room temperature to allow for crosslinking. The beads were then washed once with 50 mM Tris (pH = 7.5) to stop the crosslinking reaction, and twice with 0.1% Triton X-100 in PBS. The washing solution was removed by vacuum aspiration, and the beads were resuspended in PBS to make a 50% bead slurry.
Brain cortex samples were weighed and 1% Triton X-100 lysis buffer (Triton X-100, 150 mM NaCl, 50 mM Tris–HCl, 1 X Roche Complete Protease Tablet) was added at a concentration of 150 mg brain tissue/μL of lysis buffer. The samples were then sonicated (2 rounds of 20 1-sec pulses) and centrifuged at 14,000 rpm for 30 min. The supernatant was collected and used for subsequent immunoprecipitation steps. Brain lysates and cell media were pre-cleared with beads not conjugated to antibody by tumble incubating the samples with 50 μL of the 50% bead slurry for 4 h at 4°C. The pre-cleared lysate and media samples were then tumble incubated with antibody-conjugated beads overnight at 4°C. The beads were then washed 3 times with PBS and 3 times with 25 mM triethylammonium bicarbonate (TEABC). Following the last TEABC wash, the TEABC was removed via vacuum aspiration with a pipette tip. Formic acid was then added to the beads to elute the bound proteins, and the mixture was vortexed for 20 min. The beads were then centrifuged at 14,000 rpm for 5 min and the supernatant was collected from the beads. The formic acid supernatant was transferred to a new microcentrifuge tube and evaporated in a Savant SpeedVac for 60 min (37°C). The dried proteins were then resuspended in 20% acetonitrile/80% 25 mM TEABC and vortexed for 30 min. The samples were then digested with 500 ng of mass spectrometry-grade trypsin (Promega) and incubated at 37°C for 16 h. The digested samples were dried again by vacuum evaporation, resuspended in 10% acetonitrile and 0.1% formic acid in water, and transferred to mass spec vials.
Liquid chromatography/mass spectrometry
LC-MS/MS measurements were performed on a Waters Xevo TQ-S triple quadrupole mass spectrometer (Waters Inc., Milford, MA) coupled to a Waters nano-ACQUITY ultra performance liquid chromatography (UPLC) system, equipped with a Waters nano-ESI ionization source. To identify multiple reaction monitoring (MRM) transitions, the synthetic apoE peptide LQAEIFQAR and synthetic Aβ peptide LVFFAEDVGSNK were purchased from AnaSpec, Inc. (Fremont, CA), and directly infused into the LC-MS for automatic tuning of optimized MRM transitions produced by the peptide. For both the apoE and Aβ peptide, optimal conditions were identified as a capillary voltage of 3.3 kV, source temperature of 80°C, cone voltage of 52 V, purge gas flow rate set at 100 L/hr, and cone gas at 50 L/hr. Obtained MRM transitions (Table
1) were then validated by the analysis of apoE and Aβ cell culture media standards. For the actual experiments, all digested peptide samples were kept at 4°C and 1 μL aliquots were injected onto a Waters BEH130 nanoAcquity UPLC column (C18 particle, 1.7 μm, 100 μm × 100 mm). The peptide mixtures were separated on a reverse-phase nanoUPLC operated at a flow rate of 500 nL/min with a gradient mixture of solvents A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile). For apoE, the column was initially kept at 99% solvent A for 1.5 min, followed by a separation gradient of 1% to 97% solvent B from 1.5 to 18 min. The column was then kept at 97% solvent B for another 5 min followed by 1% solvent B to re-equilibrate for 10 min to prepare for the next injection. For Aβ, the column was initially kept at 90% solvent A for 7.0 min, followed by a separation gradient of 10% to 45% solvent B from 7 to 12 min. The column was then kept at 45% to 95% solvent B from 12 to 14 min, and at 95% solvent B for another 3 min followed by 10% solvent B to re-equilibrate for 15 min to prepare for the next injection. All raw data were acquired and quantified using Waters MassLynx 4.1 software suite. The labeled/unlabeled ratio was obtained by dividing the area under the curve (AUC) of the MRM total ion for the labeled peptide by the AUC for the unlabeled peptide, and converted to tracer-to-tracee ratios (TTRs) by reference to the standard curve.
Gas chromatography/mass spectrometry
The free leucine tracer-to-tracee ratio was measured from the mouse plasma using GC/MS. Plasma proteins were precipitated with ice-cold acetone, and lipids were extracted using hexane solvent. The resulting aqueous fraction was then dried with a vacuum (Savant Instruments, Farmingdale, NY) and converted to t-butyldimethylsilyl derivatives. The free leucine TTR was then measured by monitoring ions with m/z ratios of 200 (unlabeled) and 203 (labeled) [
52].
Kinetic analysis
The mice were in steady-state conditions, since the amount of apoE and Aβ did not significantly change over the time period of the kinetic analysis. This was determined by measuring the protein level (via ELISA as described below) for the cohorts of mice at each time point following the stable isotope injection, and comparing across groups. At metabolic steady state, the fraction of the pool that is synthesized per unit time equals the fraction of the pool catabolized per unit time (FCR), which can be calculated as the negative of the slope of the natural log of TTR plotted over time [
53]. Production rates (PRs) were determined as: PR (protein amount/mg/hr) = [FCR (pools/hr) × protein concentration (protein amount/mL) × lysate volume (mL)]/brain weight (mg). The half-lives (t
½) were calculated using the equation t
½ = ln 2/FCR. Protein concentrations of apoE and Aβ in the lysates were determined by protein-specific sandwich ELISAs using in-house antibodies. For apoE, HJ6.2 was used as the coating antibody and biotinylated HJ6.3 as the detection antibody. Pooled C57/BL/6 J mouse plasma was used as a standard. For Aβ, HJ2 (anti-Aβ35-40) and biotinylated HJ5.1 (anti-Aβ13-28) were used as the coating and detection antibody, respectively.
Statistical analysis
Data were analyzed using GraphPad Prism Software and presented as mean ± standard error of the mean (SEM). For analyzing differences in protein levels and production rates, a two-tailed student’s t-test was used. Differences in the FCR values were compared using analysis of covariance (ANCOVA) of the negative of the slope of the natural log of TTR plotted over time, which was determined using linear regression analysis.
Competing interests
DMH and RJB co-founded and are on the scientific advisory board of C2N Diagnostics. BWP provides consultation services for tracer turnover kinetics for C2N Diagnostics.
Authors’ contributions
JMB, JK, and DMH conceived and designed the experiments. JMB, JK, HJ, and MP labeled mice and collected mouse tissue. JMB and HJ performed all MS sample preparation. YP, KRW, and RJB performed and optimized MS data collection and analysis. BWP assisted with kinetic analysis and interpretation. JMB, JK, BWP, and DMH wrote the paper. All authors revised the manuscript for important intellectual content and gave final approval of the version to be published.